专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022067724A1 一种SGLT-2抑制剂·肌氨酸共晶体及其制备方法和应用审中-公开
公开(公告)号：WO2022067724A1
公开(公告)日：2022-04-07
申请号：PCT/CN2020/119547
申请日：2020-09-30
申请人：北京睿创康泰医药研究院有限公司 , 天津睿创康泰生物技术有限公司
发明人：贾慧娟 , 侯伟 , 任晓慧 , 郭亮 , 董艳阳
IPC分类号： C07H7/04 , C07D409/10 , C07D309/10 , A61K31/7042 , A61P3/10 , A61P13/12 , A61P9/00
摘要：提供了一种SGLT-2抑制剂·肌氨酸共晶体及其制备方法和应用。以肌氨酸为配体，具有较高的安全性和较低的成本；药物共晶体具有较高的稳定性，在制剂组合物生产过程或贮藏过程中，晶型不易发生改变；不会遇热熔融，不会发生粘冲、聚团或产生静电，具有更好的混合均匀性；在制备的药物组合物中分布均匀，使得药物组合物具有更好的体内释放、吸收和药效，且批间差异小；具有较高的稳定性，更利于贮藏、运输；制备工艺简单，重现性高，且析晶时间短，工艺条件要求低，具有更高的经济效益；制备过程中不使用不安全溶剂；可同时对SGLT-2抑制剂粗品或中间体进行纯化。

2. 发明申请

WO2022053576A1 NEW FLUORINATED HEXOSES 审中-公开
公开(公告)号：WO2022053576A1
公开(公告)日：2022-03-17
申请号：PCT/EP2021/074852
申请日：2021-09-09
申请人： STICHTING KATHOLIEKE UNIVERSITEIT
发明人： PIJNENBORG, Johan Franciscus Adrianus , BOLTJE, Thomas Jan , ROSSING, Emiel
IPC分类号： C07D309/10 , A61K31/351 , C07H19/207 , C07H11/04
摘要： The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying cancer, tumor metastasis, inflammation, infections, or genetic disorders.

3. 发明申请

WO2021245253A1 PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN 审中-公开
公开(公告)号：WO2021245253A1
公开(公告)日：2021-12-09
申请号：PCT/EP2021/065044
申请日：2021-06-04
申请人： KRKA, D.D., NOVO MESTO
发明人： POLOVIC, Aleš , BENKIC, Primoz , OSTERMAN, Nika , GRUBAR, Mateja , VOVKO, Jernejka , KOBAL, Tjaž , KUFNER, Monika
IPC分类号： C07D309/10
摘要： A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more other active substances and methods for making the same.

4. 发明申请

WO2021227441A1 芳基葡糖苷衍生物及其在药物中的用途审中-公开
公开(公告)号：WO2021227441A1
公开(公告)日：2021-11-18
申请号：PCT/CN2020/131253
申请日：2020-11-24
申请人：上海喆邺生物科技有限公司
发明人：杜锋田 , 王海波 , 张强
IPC分类号： C07D309/10 , C07H5/00 , C07C15/16 , A61P9/00 , A61P3/10 , A61K31/70 , A61K31/351
摘要：一种抑制钠葡萄糖协同转运蛋白1的化合物及其药学上可接受的盐和立体异构体。该化合物用于药物组合物，以及其制备和使用的方法，包括药物及其组合物在制备用于治疗和改善糖尿病，心脑血管疾病，降低体重，脂肪肝，便秘，代谢相关疾病和肿瘤治疗中应用。

5. 发明申请

WO2021211765A1 HYDROGENATION OF NEPETALACTONE 审中-公开
公开(公告)号：WO2021211765A1
公开(公告)日：2021-10-21
申请号：PCT/US2021/027362
申请日：2021-04-14
申请人： ZYMERGEN INC.
发明人： KOSINSKI, Szymon , LOPEZ, Liza , CHAU, Wilson , GURAM, Anil , LOUIE, Ying Lin
IPC分类号： C07D309/10 , B01J23/755 , A01N43/16
摘要： A process for the production of dihydronepetalactone including hydrogenating nepetalactone in the presence of a catalytic metal is provided. The catalytic metal may include nickel. The process may be performed in an aqueous medium.

6. 发明申请

WO2021083209A1 SSAO INHIBITORS AND USE THEREOF 审中-公开
公开(公告)号：WO2021083209A1
公开(公告)日：2021-05-06
申请号：PCT/CN2020/124381
申请日：2020-10-28
申请人： ECCOGENE (SHANGHAI) CO., LTD.
发明人： REN, Zaifang , SUN, Xuefeng , XU, Qing
IPC分类号： C07D309/04 , C07D319/12 , C07D309/10 , C07D309/08 , C07C317/14 , C07D307/10 , C07D309/12 , C07D211/46 , C07D309/06 , C07D205/04 , C07D275/02 , C07D207/06 , C07D401/04 , C07D295/08 , A61K31/10 , A61P3/00 , A61P9/00 , A61P29/00
摘要： Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

7. 发明申请

WO2020050361A1 β－Ｃ－アリールグリコシド誘導体の製造方法审中-公开
公开(公告)号：WO2020050361A1
公开(公告)日：2020-03-12
申请号：PCT/JP2019/034981
申请日：2019-09-05
申请人：株式会社トクヤマ
发明人：関　雅彦
IPC分类号： C07D309/10 , C07B61/00
摘要：式（２）で表されるＣ－アリール－ヒドロキシグリコシド誘導体の還元反応が低温で速やかに進行し、式（１）で表されるβ－Ｃ－アリールグリコシド誘導体を高選択的かつ高収率で製造する方法を提供することを目的とし、かかる目的を達成するために、本発明は、式（２）で表されるＣ－アリール－ヒドロキシグリコシド誘導体を、チタン化合物の存在下、シラン化合物と接触させて、式（１）で表されるβ－Ｃ－アリールグリコシド誘導体を製造する工程を含む方法を提供する。

8. 发明申请

WO2019166958A1 PROCESS FOR THE PREPARATION OF SOTAGLIFLOZIN 审中-公开
公开(公告)号：WO2019166958A1
公开(公告)日：2019-09-06
申请号：PCT/IB2019/051559
申请日：2019-02-27
申请人： MYLAN LABORATORIES LTD
发明人： JAYACHANDRA, Sureshbabu , SETHI, Madhuresh , KAUSHIK, Vipin, Kumar , RAVI, Vijaya, Krishna , POTHANI, Jayaram , PRATHI, Sivakoteswara, Rao
IPC分类号： C07D309/10
摘要： Sotagliflozin may be prepared using schemes and intermediates disclosed herein. Sotagliflozin may be incorporated into pharmaceutical dosage forms for treatment of diabetes.

9. 发明申请

WO2019145726A9 COMPOUNDS 审中-公开
公开(公告)号：WO2019145726A9
公开(公告)日：2019-08-01
申请号：PCT/GB2019/050209
申请日：2019-01-25
申请人： ENTERPRISE THERAPEUTICS LIMITED
发明人： COLLINGWOOD, Stephen , MCCARTHY, Clive , HARGRAVE, Jonathan, David , HAY, Duncan, Alexander , SCHOFIELD, Thomas, Beauregard , ELLAM, Sarah , BUXTON, Craig , HABGOOD, Matthew , INGRAM, Peter , MA, Chun Yan , NAPIER, Spencer , SHAIKH, Abdul , SMITH, Matthew , STIMSON, Christopher , WALKER, Edward
IPC分类号： C07D213/72 , C07D309/10 , C07C1/00 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61P11/00
摘要： Compounds of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b X 1 , X 2 , Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

10. 发明申请

WO2018193273A1 ANTIMICROBIAL AGENTS 审中-公开
公开(公告)号：WO2018193273A1
公开(公告)日：2018-10-25
申请号：PCT/GB2018/051058
申请日：2018-04-23
申请人： THE UNIVERSITY OF WARWICK
发明人： CHALLIS, Gregory Leonard , JIAN, Xinyun , HOBSON, Christian , MASSCHELEIN, Joleen Solange Liesbet
IPC分类号： C07C69/732 , C07C235/28 , A61K31/232 , A61P31/00 , C12N1/00 , C07D309/10
摘要： The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii . Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NR x (where R* is either H or C 1-3 alkyl, e.g. CH 3 ); R 1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R 1 is an optionally substituted straight-chained or branched C- 1-6 alkyl group (e.g. C 1-3 alkyl group); R 2 is H, F, CI, Br, I or CH 3 ; R 3 is H or OH; R 8 is a straight-chained or branched C 1-8 alkyl group (e.g. a C 1-6 aikyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R 9 is H, F, CI, Br or I; R 4 and R 5 are independently selected from H and OH, or R 4 and R 5 together are =0, preferably R 4 is H and R 5 is OH; R 6 is H, F, CI, Br, I or CH 3 ; R 7 is H and R 7' is OH, or R 7 and R 7' together are =0, preferably R7 is H and R7' is OH); and each— independently represents an optional bond (i.e. each of C 2 -C 3 , C 4 -C 5 , C 6 -C 7 , C 8 -C 9 and C 10 -C 11 are independently either C-C (single) or C=C (double) bonds).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式